Metabolic / NAD+
Prepared by the ezGLP team. Sources last checked .
Also known as 5-Amino-1-methylquinolinium, 5A1MQ, 5-Amino-1MQ iodide
Routes represented in the knowledgebase: Subcutaneous (SubQ).
5-Amino-1MQ is listed in the ezGLP knowledgebase under Metabolic / NAD+. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
Serious or important: potential immunogenicity, aggregation, impurity, or product-quality risks.
A dependable route-specific human interaction and side-effect profile is not established; this is not evidence of no risk.
Safety evidence sourceThese are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
NAD+ and BPC-157 are proposed as complementary for cellular-energy and tissue-repair goals, but no direct animal or human combination study has established synergy or safety.
Interaction evidence sourceNAD+ evidence reviewFDA BPC-157 safety assessmentSS-31 plus the NAD+ precursor NMN produced complementary cardiac effects in aged mice, providing an indirect rationale for interest in SS-31 with NAD+.
Interaction evidence sourceNAD+ evidence reviewElamipretide labelNNMT inhibition by 5-Amino-1MQ-related compounds increased intracellular NAD+ in preclinical work, creating an indirect combination hypothesis.
Interaction evidence source5-Amino-1MQ preclinical studyNAD+ evidence reviewSummarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.
